A Study of JNJ-78278343 and JNJ-95298177 for Prostate Cancer
Phase 1
140
about 2.2 years
18+
Male only
4 sites in FL, NY, OH +1
What this study is about
This trial is testing a treatment combination (JNJ-78278343 and JNJ-95298177) to see if it's safe and effective in treating prostate cancer. The goal is to find the best dose of this combination for people with advanced, hormone-resistant prostate cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take JNJ-78278343
- 2.Take JNJ-95298177
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants With Adverse Events (AEs) by Severity, Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)
Secondary: Duration of Response (DOR), Objective Response Rate (ORR), Prostate-Specific Antigen (PSA) Response Rate, Radiographic Progression-Free Survival (rPFS), Time to Response (TTR)
Oncology